Long-term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Our data confirmed the sustained effectiveness of AB without new safety concerns. Surgical/locoregional treatments after the start of AB and liver decompensation were common, highlighting the need for a multidisciplinary and integrated approach in advanced HCC.

Authors

Institutions

Publication Details

Journal
Hepatology
Published
2026-02-25
DOI
https://doi.org/10.1097/hep.0000000000001725
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real-world study

GIANLUCA MASI, Luca Ielasi, Stefania De Lorenzo, F. Marra et al.
Hepatology
Hepatocellular Carcinoma Treatment and Prognosis
article

Long-term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real-world study

GIANLUCA MASI, Luca Ielasi, Stefania De Lorenzo, F. Marra, Piera Federico, Caterina Vivaldi, Leonardo Stella, Andrea Palloni, Rodolfo Sacco, Mariangela Bruccoleri, Francesca Romana Ponziani, Pierluigi Toniutto, SARA LONARDI, Chiara Mazzarelli, Rosanna Villani, Svegliati-Baroni Gianluca, Ciro Celsa, T Pressiani, Andrea Dalbeni, Lorenzo Lani, On behalf of the Dutch CPE Surveillance Study Group, Massimo Iavarone, Alessandra Auriemma, Fabio Piscaglia, Giuseppe Cabibbo, Alessio Mastro, Lorenza Rimassa
article en

Abstract

Our data confirmed the sustained effectiveness of AB without new safety concerns. Surgical/locoregional treatments after the start of AB and liver decompensation were common, highlighting the need for a multidisciplinary and integrated approach in advanced HCC.

Hepatology
Università Cattolica del Sacro Cuore (IT), University of Foggia (IT), University of Verona (IT), Marche Polytechnic University (IT), University of Udine (IT), Humanitas University (IT), University of Milan (IT), Hammersmith Hospital (GB), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ospedale Maggiore (IT), Ospedale degli Infermi (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Istituto Oncologico Veneto (IT), Department of Health (ES), Centro Clinico Nemo (IT), Azienda USL di Bologna (IT), Ospedale per gli Infermi (IT), Ospedale Santa Maria della Misericordia di Udine (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT), Imperial College London (GB), University of Palermo (IT), University of Bologna (IT)
Good health and well-being
Openalex Percentile: Top 44%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.